Platinum Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Platinum Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,157	Closed	-$3.43M	–	155
2021 Q2	$3.43M	Sell	21,157 -16,068	-43%	-$1.25M	0.08%	76
2021 Q1	$2.99M	Sell	37,225 -7,738	-17%	-$519K	0.07%	73
2020 Q4	$2.45M	Sell	44,963 -20,068	-31%	-$729K	0.06%	84
2020 Q3	$1.29M	Sell	65,031 -18,706	-22%	-$390K	0.03%	100
2020 Q2	$1.76M	Hold	83,737	–	–	0.04%	91
2020 Q1	$1.02M	Buy	83,737 +17,567	+27%	+$237K	0.03%	99
2019 Q4	$971K	Hold	66,170	–	–	0.02%	88
2019 Q3	$883K	Sell	66,170 -54,684	-45%	-$872K	0.02%	85
2019 Q2	$1.98M	Hold	120,854	–	–	0.05%	59
2019 Q1	$2.06M	Buy	120,854 +13,913	+13%	+$207K	0.05%	63
2018 Q4	$1.46M	Buy	106,941 +51,941	+94%	+$965K	0.05%	62
2018 Q3	$1.57M	Hold	55,000	–	–	0.04%	62
2018 Q2	$1.5M	Hold	55,000	–	–	0.04%	61
2018 Q1	$1.16M	Buy	+55,000	New	+$1.35M	0.03%	67

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Platinum Investment Management's NTLA Position: Q3 2021 in Review

Platinum Investment Management sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 21,157 shares — an estimated $3.43M sold.

Platinum Investment Management first reported a position in NTLA in Q1 2018 and held it in 14 quarters. The position peaked at $3.43M in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

Platinum Investment Management reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
Platinum Investment Management sold 21,157 Intellia Therapeutics shares in Q3 2021, an estimated $3.43M.
Platinum Investment Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 14 quarters.
Platinum Investment Management's Intellia Therapeutics position peaked at $3.43M in Q2 2021.
364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Platinum Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.